Hutch News

Hutch News

Stories tagged 'Marco Mielcarek'

Good News at Fred Hutch

Celebrating faculty and staff achievements

Dec. 22, 2016

For fourth year in a row, Fred Hutch/SCCA transplant rates among best in the U.S.; immuntherapy symposium available on video for those who couldn't attend the event

View story >


Good News at Fred Hutch

Celebrating faculty and staff achievements

Feb. 4, 2016 | By Fred Hutch News Service staff

Drs. Marie Bleakley and Soheil Meshinchi receive $1M to design targeted immunotherapies for childhood leukemia; pancreatic cancer treatment advancing in clinical trials; novel mathematical model could transform dosage selection for clinical trials; new global initiative for breast cancer has roots in Seattle; Dr. Colin Correnti speaks at inaugural SHIFT 2016

View story >


Life with graft-vs.-host disease: When the transplant is just the beginning

How researchers are trying to combat this common, often debilitating side effect of treatment

April 21, 2015 | By Rachel Tompa / Fred Hutch News Service

Up to 70 percent of transplant recipients, such as Greg Grappone, develop acute graft-vs.-host disease, which crops up within the first few months of treatment, and 40 percent get chronic GVHD, the form that appears more than 100 days post-transplant. As the name implies, the chronic condition can last for years — or a lifetime — and its symptoms range from mildly annoying to disabling to life-threatening.

View story >


Gentler treatment effective for many with graft-vs.-host disease

A new study finds halving standard steroid dose treats most acute GVHD just as well; could limit dangerous side effects

Feb. 19, 2015 | By Dr. Rachel Tompa / Fred Hutch News Service

Up to 70 percent of transplant patients develop acute graft-vs.-host disease. Standard treatment for GVHD, the steroid prednisone, carries its own host of side effects. Fred Hutch's Dr. Marco Mielcarek led a new study testing lower doses of prednisone in patients with acute GVHD -- with promising results.

View story >


Mielcarek lands $2.2 million GVHD grant

NHLBI grant will expand research into protective mechanisms of statins against severe acute graft-vs.-host disease in transplant patients

May 16, 2011 | By Dean Forbes

The Fred Hutchinson Cancer Research Center Clinical Research Division’s Dr. Marco Mielcarek has received $2.2 million from the National Institutes of Health’s National Heart, Lung and Blood Institute to continue research on whether statin treatment is effective at reducing the risk of graft-vs.-host disease in patients receiving an allogeneic stem cell transplant. While statins are a class of drugs for treating high cholesterol, they also have immune-modulating effects.

View story >


Post-transplant survival: A study of the gap between ethnic groups

Mielcarek, colleagues cite transplant-diagnosis delays among possible reasons for poor survival rates for African-American patients

July 21, 2005 | By COLLEEN STEELQUIST

View story >



GIVE NOW &
SAVE LIVES

Support our quest for cures

Story Archive


Publications

Hutch Magazine
Our quarterly magazine

Annual Report
Fiscal year highlights

Science Spotlight
Monthly review of Center-authored papers



Fred Hutch News

        Get updates via email.